R&D Pipeline Overview

We have established a robust and risk-balanced portfolio focusing on treating diseases currently having few or no therapeutic options.  While most of the products in the pipeline are in-licensed from universities or big pharma, sponsored-research activities have also been initiated with selected universities for future product candidates.  LifeMax currently has 2 products at clinical stage and 2 products at preclinical stage.

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Monogenic rare disease

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Treating Orphan Diseases With Few or No Therapeutic Options.

map.png

Redwood City, CA, USA

map.png

Taipei, Taiwan

©2020 BY LIFEMAX HEALTHCARE INTERNATIONAL